<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4614">
  <stage>Registered</stage>
  <submitdate>9/09/2014</submitdate>
  <approvaldate>9/09/2014</approvaldate>
  <nctid>NCT02239081</nctid>
  <trial_identification>
    <studytitle>A Safety and Tolerability Study of CTP-730 in Healthy Volunteers</studytitle>
    <scientifictitle>A Randomized, Double-blind, Single Ascending Dose, Safety, Tolerability, Pharmacokinetics Study of CTP-730 in Healthy Volunteers</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CP730.1001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Healthy</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - CTP-730
Treatment: drugs - Placebo for CTP-730

Experimental: CTP-730, 5 mg - oral suspension, once daily.

Experimental: CTP-730, 10 mg - Oral Suspension, once daily.

Experimental: CTP-730, 20 mg - Oral Suspension, once daily.

Experimental: CTP-730, 30 mg - Oral Suspension, once daily.

Experimental: CTP-730, 40 mg - Oral Suspension, once daily.

Experimental: CTP-730, 50 mg - Oral Suspension, once daily.

Experimental: CTP-730, 60 mg - Oral Suspension, once daily.


Treatment: drugs: CTP-730


Treatment: drugs: Placebo for CTP-730


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Number and severity of adverse events</outcome>
      <timepoint>3 days</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Pharmacokinetics parameters - Peak plasma concentration - Cmax by dose Area under the plasma concentration by time - AUC by dose</outcome>
      <timepoint>96 hours</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Healthy male and female volunteer subjects, 18 to 50 years of age, inclusive.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>50</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Current significant medical condition, laboratory abnormality, or psychiatric illness

          -  History of clinically significant central nervous system (eg, seizures), cardiac,
             pulmonary, metabolic, renal, hepatic, or gastrointestinal (GI) conditions

          -  PR interval = 220 msec or QRS duration = 120 msec or QTcB / QTcF interval &gt; 450 msec

          -  Elevated liver function tests greater than twice the upper limit of normal

          -  Positive blood screen for human immunodeficiency virus (HIV antibody), hepatitis B
             virus surface antigen, or hepatitis C virus antibody

          -  Urinalysis positive for protein or glucose

          -  A positive screen for alcohol, drugs of abuse, or tobacco use.

          -  Inability to comply with food and beverage restrictions during study participation

          -  Donation or blood collection or acute loss of blood prior to screening</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Basic Science</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/09/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>55</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/05/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA</recruitmentstate>
    <hospital>CMAX - Adelaide</hospital>
    <postcode>5000 - Adelaide</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Concert Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a Phase 1, single center, single-ascending dose, randomized study</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02239081</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Ginny Braman</name>
      <address>Concert Pharmaceuticals, Inc.</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>